KLK3 and benign prostatic hyperplasia: However, a more recent study by Condappa et al. (2020) [82] found no statistically significant differences in cfDNA concentration or integrity between PC and BPH patients (cfDI: 0.62 vs. 0.67; p = 0.342), nor any meaningful associations with clinical parameters such as PSA levels or Gleason score.